Rapid Antibody Discovery Service for ADC Therapy using High-Diversity Premade Antibody Library

Background Solution Workflow Antibody Libraries FAQ Online Inquiry

The development of next-generation Antibody-Drug Conjugates (ADCs) demands an antibody with exceptional specificity, high affinity, and efficient internalization capabilities. The traditional antibody discovery process can be a significant bottleneck, consuming valuable time and resources. Creative Biolabs, with over two decades of leadership in antibody engineering, provides a powerful solution: a world-class antibody discovery service leveraging our extensive, pre-constructed phage display antibody libraries. This strategic approach dramatically accelerates your project timeline, enabling the rapid identification of superior antibody candidates optimized for ADC development.

Discuss Your Project Today

The Critical Challenge: Finding the Right Antibody for Your ADC

An ADC's success is fundamentally dependent on the quality of its antibody component. An ideal antibody for ADC therapy must not only bind to its target antigen with high specificity and affinity but also trigger receptor-mediated endocytosis to deliver the cytotoxic payload into the cancer cell.

Key challenges include:

Internalization Efficiency: Not all antibodies are efficiently internalized upon binding. Screening for this specific functional characteristic is paramount.
Affinity and Specificity: The antibody must bind tightly to the tumor-associated antigen while minimizing off-target binding to healthy tissues to reduce toxicity.
Developability: The candidate must possess favorable biophysical properties, including high expression, stability, and low immunogenicity.
Epitope Coverage: Accessing a diverse range of epitopes can be crucial for identifying antibodies with unique functional properties.

Structure and action mechanism of ADC. (OA Literature). Fig.1 Structure and mechanism of action of ADC.³

The Creative Biolabs Solution: Speed and Precision with Premade Antibody Libraries

Our Premade Antibody Library platform is designed to overcome these challenges. Instead of building a custom library for each project—a process that can take months—we start with vast, validated libraries containing billions of unique antibody fragments. This allows us to move directly to the screening and selection phase, delivering high-quality candidates in a fraction of the time.

Table 1. Advantages of Our Premade Antibody Library Platform for ADC Development

Advantage	Description	Benefit to Your ADC Program
Unparalleled Speed	By eliminating the need for immunization or custom library construction, we can deliver a panel of antibody hits in as little as 4-6 weeks.	Accelerate your R&D pipeline and gain a competitive edge by moving your ADC candidate toward clinical trials faster.
Exceptional Diversity	Our libraries (e.g., Human Fab, scFv) have diversities exceeding 10¹⁰, ensuring comprehensive epitope coverage against your target.	Increase the probability of success by identifying rare antibodies with unique binding properties and high affinity.
Optimized for ADCs	Our screening strategies are specifically designed to isolate antibodies that not only bind but also efficiently internalize, a critical feature for payload delivery.	De-risk your project early by selecting for functionally relevant antibodies from the start, improving the therapeutic index of your final ADC.
Reduced Immunogenicity	The majority of our libraries are of human origin, significantly minimizing the potential for immunogenic responses in patients.	Enhance clinical safety and efficacy by starting with fully human antibody frameworks.
Proven Expertise	Our team of Ph.D.-level scientists has a deep track record of success in isolating therapeutic antibody candidates for global pharmaceutical partners.	Leverage our experience to navigate complex discovery challenges and ensure your project is guided by industry-leading experts.

Our Streamlined Antibody Discovery Workflow for ADCs

Creative Biolabs has refined a multi-stage workflow to ensure the efficient identification and validation of optimal antibody candidates for your ADC program.

Step 1: Target Analysis and Library Selection

We work closely with you to understand your target antigen and project goals. Based on this, we select the most appropriate premade antibody library (e.g., human, synthetic, scFv, Fab) from our extensive collection to maximize the chances of success.

Step 2: Multi-Round Biopanning & Advanced Screening

High-throughput screening is performed against your target protein. We employ a combination of solid-phase, solution-phase, and cell-based panning strategies to isolate high-affinity binders. Crucially, we integrate ADC-specific pressure, such as screening on live cells, to enrich for internalizing antibodies.

Step 3: Hit Characterization and Lead Candidate Identification

Positive clones are sequenced and expressed as full-length IgG antibodies. A preliminary characterization panel is performed, including:

ELISA for binding confirmation
SPR/BLI for affinity measurement (K D)
Initial cell-based binding assays (FACS)

Step 4: ADC-Specific Functional Assays

Lead candidates undergo rigorous functional testing critical for ADC development. This includes:

Antibody Internalization: Using state-of-the-art methods (e.g., pH-sensitive dyes, confocal microscopy) to quantify internalization rates and efficiency.
Cytotoxicity Assays: Preliminary evaluation of the antibody's potential to deliver a cytotoxic payload.
Epitope Binning: To ensure a diverse set of lead candidates targeting different epitopes.

Step 5: Sequence, Data, and Deliverables

Upon project completion, you receive a comprehensive data package, including all characterization results, and the unique sequences of your lead antibody candidates, ensuring full IP ownership for your program.

Explore Our Premier Collection of Premade Antibody Libraries

Creative Biolabs offers a diverse portfolio of libraries to suit any ADC discovery project.

Human Antibody Libraries: Our primary offering for therapeutic development, featuring scFv and Fab formats with immense diversity for identifying candidates with low immunogenicity.
Synthetic Antibody Libraries: Designed with optimized frameworks and precisely controlled diversity at key CDR positions, allowing for the isolation of antibodies with superior biophysical properties.
Immune Antibody Libraries: While our focus is on premade, we can also leverage immune libraries from various species (mouse, rabbit, chicken, etc.) if your project requires it.

Libraries	Library ID	Display Technology	Library Format	Species	Library Size
Phage display human scFv libraries	HuScL-2	Phage Display	scFv	Human	1.42×10⁹
	HuScL-4	Phage Display	scFv	Human	2.0×10⁹
	HuScL-6	Phage Display	scFv	Human	1.0×10¹¹
	HuScL-7	Phage Display	scFv	Human	1.1×10¹⁰
Phage display human Fab libraries	HuFabL-4	Phage Display	Fab	Human	1.9×10¹⁰
	HuFabL-5	Phage Display	Fab	Human	1.1×10¹⁰
	HuFabssL-1	Phage Display	Fab	Human	1.8×10¹⁰

Phage display mouse antibody libraries
Phage display Rabbit Fab library
Phage display Chicken library
Phage display sdAb libraries (camel, llama)

Creative Biolabs also provides antibody discovery services for different types of targets to suit a variety of applications:

Frequently Asked Questions (FAQs)

Q: How long does the entire process take from target to lead candidate?

A: Our premade library approach is incredibly efficient. We can typically deliver a panel of well-characterized, high-affinity antibody hits in approximately 6-8 weeks.

Q: What kind of targets can you work with?

A: We have successfully screened against a wide range of targets, including purified recombinant proteins, peptides, and complex cell-surface antigens on live cells.

Q: Do I retain the intellectual property (IP) for the discovered antibodies?

A: Absolutely. Creative Biolabs operates on a fee-for-service basis. Our clients retain full intellectual property rights to all antibody sequences discovered and developed during the project.

Q: What is the typical affinity of antibodies discovered from your libraries?

A: We routinely isolate antibodies with affinities in the low nanomolar to high picomolar range directly from our primary screenings. If required, our affinity maturation platform can further improve this to the single-digit picomolar range.

Advance Your ADC Program Today

Partner with a global leader in antibody discovery. Contact our team of experts to discuss your project and learn how our premade antibody libraries can accelerate your path to the clinic.

Contact Us Today for a Free Quote!

References

Lura, Njål, et al. "Tumor ADC value predicts outcome and yields refined prognostication in uterine cervical cancer." Cancer Imaging 25.1 (2025): 23. https://doi.org/10.1186/s40644-025-00828-6
Fournier, Léxane, et al. "A platform for the early selection of non-competitive antibody-fragments from yeast surface display libraries." Biological Chemistry 405.11-12 (2024): 765-775. https://doi.org/10.1515/hsz-2024-0102
Tsuchikama, K. and An, Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & cell. 2018, 9(1), pp.33-46. Under Open Access license CC BY 4.0, without modification. https://doi.org/10.1007/s13238-016-0323-0

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.